GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galmed Pharmaceuticals Ltd (FRA:GPH) » Definitions » Short Interest

Galmed Pharmaceuticals (FRA:GPH) Short Interest


View and export this data going back to 2014. Start your Free Trial

What is Galmed Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Galmed Pharmaceuticals's Short Interest

For the Biotechnology subindustry, Galmed Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galmed Pharmaceuticals's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galmed Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Galmed Pharmaceuticals's Short Interest falls into.


;
;

Galmed Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galmed Pharmaceuticals Ltd (FRA:GPH) » Definitions » Short Interest
Comparable Companies
SCNI SXTP THAR MTNB ELAB QLGN GRTX ENVB REVB PBM VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
GLMD:USA
Address
16 Abba Hillel Road, Ramat Gan, ISR, 5250608
Website
https://www.galmedpharma.com
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.

Galmed Pharmaceuticals Headlines

No Headlines